Latest:
Dr. Flaherty on the Significance of the NCI-MATCH Precision Medicine Trial
Keith T. Flaherty, MD, discusses the significance of the NCI-MATCH study.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Kelin Wang, PhD
Latest:
A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures
Kelly Bailey, MD, PhD
Latest:
Dr. Bailey Discusses the Treatment of Pediatric Patients With Sarcoma
Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses the treatment of pediatric patients with sarcoma.
Kelly Blair
Latest:
Choosing a Care Model and Making It Work
In June, CMS selected roughly 200 medical oncology practices to participate in the public payer’s own flavor of oncology payment reform: the Oncology Care Model. This program, which launched in July, is designed to lower costs and improve quality of care for treatment episodes that start with a six-month chemotherapy regimen.
Kelly Davio
Latest:
Frontline Venetoclax/Obinutuzumab Combo Emerges as Treatment Option for CLL With CKT
Othman Al-Sawaf, MD, discusses findings from the CLL14 trial, the rationale for exploring this proposed combination, and shares his thoughts on the emerging treatment paradigms in chronic lymphocytic leukemia.
Kelly Hunt, MD
Latest:
Dr. Hunt on Treating Local Regional Recurrence in Breast Cancer
Kelly Hunt, MD, professor and chair of Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with breast cancer who have local regional recurrence.
Kelly Johnson
Latest:
Payers Still Denying Coverage Despite Clinical Trial Mandate
A mandate enacted after the 2010 Patient Protection and Affordable
Care Act was supposed to improve health coverage for patients
enrolled in clinical trials; however, nearly 63% of cancer centers
and organizations that responded to a recent survey reported
insurance denials of routine care costs associated with patient involvement
in clinical trials during 2014.
Kendra Harris, MD, MSc
Latest:
Stereotactic Body Radiotherapy Shows Potential in Oligometastatic Cancer
An increasing amount of evidence shows that a proportion of patients with cancer found to have low-volume metastases at diagnosis see meaningful benefit from aggressive local therapy. Equally important, there have been no meaningful reductions in reported quality of life among patients receiving intensive local therapy, and a small percentage of patients appear to be cured with this strategy.